3 Maternity and Critical Care Hospital Operator, Single-Use Devices Exporter and National Diagnostics Chain Stocks With a Strong Future Roadmap: Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare
- October 26, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare: ROE of 10.4% to 12.6% and FY22 to FY26 revenue CAGR of 7.6% to 20.3%. Prices as of 23 Oct 2026.
Quick Answer
The three hospital, medical device and diagnostics stocks to watch are Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare. Their return on equity ranges from 10.4% to 12.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 20.3%. Metropolis Healthcare has the highest return on equity at 12.6%, while Jupiter Life Line Hospitals has the fastest revenue growth at 20.3% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Hospital, medical device and diagnostics stocks let investors follow companies that serve a growing part of the Indian economy. Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare cover a maternity and critical care hospital operator, a single-use devices exporter and a national diagnostics chain.
This list covers three hospital, medical device and diagnostics stocks with complete current figures: Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Hospital, Medical Device and Diagnostics Stocks?
Hospital, medical device and diagnostics stocks are listed healthcare companies that run hospitals, make disposable medical devices and operate pathology labs. Their earnings depend on patient volumes, device orders, test volumes and pricing.
Hospital, Medical Device and Diagnostics Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Jupiter Life Line Hospitals | 244 | 8,007 | 42.6 | 58.4 | 11.4 | 0.41 |
| Poly Medicure | 1,444 | 15,721 | 50.2 | 59.6 | 10.4 | 0.11 |
| Metropolis Healthcare | 522.95 | 10,780 | 53.1 | 59.6 | 12.6 | 0.15 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing hospital, medical device and diagnostics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Hospital, Medical Device and Diagnostics Stocks Have a Strong Roadmap in India?
Hospital, medical device and diagnostics stocks have a strong roadmap in India because rising healthcare access, insurance cover and global sourcing of medical devices keep lifting demand across the care chain.
- Patient volumes. Better insurance cover brings more admissions.
- Device exports. Global buyers source disposable devices from India.
- Test volumes. Preventive checks lift diagnostics demand.
Why Jupiter Life Line Hospitals Features Among These Hospital, Medical Device and Diagnostics Stocks
Among the hospital, medical device and diagnostics stocks on this list, Jupiter Life Line Hospitals runs multi-speciality hospitals in Pune, Thane and Indore, with strong services in maternity, child care, critical care and advanced surgery.
Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%.
The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P/E of 42.6, below the industry P/E of 58.4.
Roadmap: The company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.
What to watch: Follow bed additions, occupancy levels and revenue per occupied bed.
Why Poly Medicure Features Among These Hospital, Medical Device and Diagnostics Stocks
Among the Pune and Indore hospital company shares on this list, Poly Medicure makes single-use medical devices such as infusion sets, syringes, catheters, blood management products and dialysis consumables, and it exports to many countries.
The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6.
Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore.
Roadmap: The company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
What to watch: Track export growth, new product approvals and plant capacity use.
Why Metropolis Healthcare Features Among These Hospital, Medical Device and Diagnostics Stocks
Among the three companies on this list, Metropolis Healthcare, headquartered in Mumbai, is a pathology and diagnostics company that runs a national network of laboratories, patient service centres and collection points, and also serves hospitals and corporate clients.
Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%.
In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6.
Roadmap: The company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
What to watch: Follow test volumes per patient and the pace at which newer regions turn profitable.
Jupiter Life Line Hospitals vs Poly Medicure vs Metropolis Healthcare on Key Financials
The table below sets the three hospital, medical device and diagnostics stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Jupiter Life Line Hospitals | 737 | 1,542 | 20.3% | 194 | 12.6% |
| Poly Medicure | 961 | 1,995 | 20.0% | 321 | 16.1% |
| Metropolis Healthcare | 1,246 | 1,671 | 7.6% | 191 | 11.4% |
Metropolis Healthcare posts the highest return on equity in this group at 12.6%. Poly Medicure has the largest FY26 revenue at Rs 1,995 crore, and Jupiter Life Line Hospitals shows the fastest revenue growth with a 20.3% compound annual rate. A useful habit with hospital, medical device and diagnostics stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Hospital, Medical Device and Diagnostics Stocks
Every theme carries risks that deserve a check before any decision. For these hospital, medical device and diagnostics stocks, the main points are: Long-term Pune and Indore hospital company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Capacity timing. New beds and labs take time to mature.
- Pricing. Health care pricing rules can affect revenue.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter hospital, medical device and diagnostics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Hospital, Medical Device and Diagnostics Stocks
Hospital, medical device and diagnostics stocks reward investors who follow demand trends, order books and margins together. Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare each have a clear plan to expand. Based on the 23 October 2026 close, Jupiter Life Line Hospitals trades at Rs 244, Poly Medicure at Rs 1,444 and Metropolis Healthcare at Rs 522.95.
Download the Univest iOS App or Univest Android App to track hospital, medical device and diagnostics stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are hospital, medical device and diagnostics stocks?
Ans. Hospital, medical device and diagnostics stocks are listed healthcare companies that run hospitals, make disposable medical devices and operate pathology labs. Their earnings depend on patient volumes, device orders, test volumes and pricing. This list looks at three of them, Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which hospital, medical device and diagnostics stocks are covered in this list?
Ans. This list covers Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare. Based on the 23 October 2026 close, Jupiter Life Line Hospitals traded at Rs 244, Poly Medicure at Rs 1,444 and Metropolis Healthcare at Rs 522.95. Their return on equity ranges from 10.4% to 12.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 20.3%.
Why do hospital, medical device and diagnostics stocks have a strong future roadmap in India?
Ans. Hospital, medical device and diagnostics stocks have a strong roadmap in India because rising healthcare access, insurance cover and global sourcing of medical devices keep lifting demand across the care chain. The main drivers are as follows. Patient volumes. Better insurance cover brings more admissions. Device exports. Global buyers source disposable devices from India. Test volumes. Preventive checks lift diagnostics demand. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Jupiter Life Line Hospitals performed financially?
Ans. Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P/E of 42.6, below the industry P/E of 58.4. Looking ahead, the company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.
How has Poly Medicure performed financially?
Ans. Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6. Looking ahead, the company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
How has Metropolis Healthcare performed financially?
Ans. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6. Looking ahead, the company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
What risks should investors check before buying hospital, medical device and diagnostics stocks?
Ans. Investors should check a few risks before buying hospital, medical device and diagnostics stocks. Capacity timing. New beds and labs take time to mature. Pricing. Health care pricing rules can affect revenue. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of hospital, medical device and diagnostics stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.